Categories: Health

AstraZeneca Downgrades Its Covid Vaccine Eficcacy from 79% to 76%

Image source: Wikimedia Commons

AstraZeneca has announced it downgraded the efficacy result of its coronavirus vaccine trial in the United States after health officials questioned the results.

The company adjusted the efficacy rate of its vaccine against Covid-19 symptoms from 79% to 76%, but said the trial results confirm it “is highly effective in adults”.

US health officials had been concerned the trial was using outdated data.

AstraZeneca said it now looked forward to getting US regulatory approval.

The US trials of the AstraZeneca jab had involved more than 32,000 volunteers, mostly in America, but also in Chile and Peru.

In the results announced on March 22, the company said the vaccine was found to be 79% effective at stopping symptomatic Covid-19 disease and was 100% effective at preventing people from falling seriously ill.

On March 23, the National Institute of Allergy and Infectious Diseases said it had been informed by data and safety officials monitoring the trial that information may have been used that provided an “incomplete view of the efficacy data”.

Netherlands Becomes Latest Country to Suspend Use of AstraZeneca Covid Vaccine

Denmark Suspends Use of AstraZeneca Covid Vaccine over Blood Clots Fear

Covid-19: Italy Stops AstraZeneca Vaccine Export to Australia

AstraZeneca Covid Vaccine Approved for EU Market

Dr. Anthony Fauci, the White House’s Chief Medical Advisor, then warned reporters the company would “likely come out with a modified statement”.

AstraZeneca’s revised results now put the vaccine’s overall efficacy at 76% instead of 79%. Among the over 65s, its efficacy rose from 80% to 85% and against severe disease it remains 100% effective.

On March 25, Mene Pangalos, an executive vice president at AstraZeneca, said: “We look forward to filing our regulatory submission for Emergency Use Authorization in the US and preparing for the rollout of millions of doses across America.”

The US had ordered 300 million doses of the Oxford-AstraZeneca vaccine when it emerged as a frontrunner in the global race to immunize people against Covid-19.

However, delays and controversies have seen three other vaccines beat it to a US rollout.

Kathryn R. Bown

Kathryn - Our health specialist likes to share with the readers the latest news from the field. Nobody understands better than her the relation between healthy mind and healthy body.

Recent Posts

Bald Eagle Officially Designated America’s National Bird After 250 Years

The bald eagle has been officially declared the national bird of the United States, after…

11 hours ago

Kazakhstan Plane Crash: Dozens Survive Azerbaijan Airlines Plane Crash Near Aktau Airport

Dozens of passengers have survived a crash involving a plane carrying 69 people in Kazakhstan,…

12 hours ago

Christmas Travel: Bad Weather and Airport Delays Affect Millions of Americans

Millions of Americans are bracing for difficult weather conditions during the Christmas holiday, with storms…

1 day ago

House Panel Votes to Release Matt Gaetz Ethics Report

The US House Ethics Committee has voted to release its report on former Republican Representative…

1 week ago

ABC News to Pay $15M to Settle Trump Defamation Suit

ABC News has agreed to pay $15 million to President-elect Donald Trump to settle a…

2 weeks ago

South Korea’s Parliament Impeaches President Yoon Suk Yeol Following Martial Law Scandal

South Korea’s parliament has voted to impeach President Yoon Suk Yeol over his failed attempt…

2 weeks ago